Search

Displaying results 221 - 230 of 279 in total
  1. Drug

    Selpercatinib

    go.drugbank.com/drugs/DB15685
    ApprovedInvestigational

    [L13604] Selpercatinib is also approved by the European Commission.

  2. Drug

    Talquetamab

    go.drugbank.com/drugs/DB16678
    ApprovedInvestigational

    Talquetamab is a IgG4-PAA bispecific G protein-coupled receptor class C group 5 member D (GPRC5D)-directed CD3 T-cell engager. It consists of two arms - anti-GPRC5D and anti-CD3 arms - linked by two interchain disulfide bonds, each arm c...

  3. Drug

    Tezepelumab

    go.drugbank.com/drugs/DB15090
    ApprovedInvestigational

    [L39504] Tezepelumab was also approved by the European Commission on September 19, 2022.[L44712]

  4. Drug

    Darvadstrocel

    go.drugbank.com/drugs/DB16581
    ApprovedInvestigationalWithdrawn

    [L39759] It is the first mesenchymal stem cell therapy approved in Europe for this therapeutic indication. … Perianal fistula is a common manifestation of Crohn’s disease and is often difficult to manage, as it may be associated with complex presentations and symptoms.

  5. Drug

    Flupirtine

    go.drugbank.com/drugs/DB06623
    Investigational

    It was approved for the treatment of pain in 1984 in Europe. It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.

  6. Drug

    Nicoboxil

    go.drugbank.com/drugs/DB12911
    ApprovedWithdrawn

    Such combination topical analgesics are only available for purchase and use (for humans) in some parts of Europe and Asia, like Germany and Australia [F11, F16]. … continued interest in the medication(s) given its demonstrated efficacy, safety, and capability to be used as an alternative musculoskeletal pain therapy option with less systemic side effects when compared

  7. Drug

    Elranatamab

    go.drugbank.com/drugs/DB15395
    ApprovedInvestigational

    [L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437]

  8. Drug

    Nirsevimab

    go.drugbank.com/drugs/DB16258
    ApprovedInvestigational

    [A254691] This is due to a modification in the Fc region of nirsevimab that grants it a longer half-time compared to typical monoclonal antibodies. … [L44146,A254571] Compared to [palivizumab], another anti-RSV antibody, nirsevimab shows greater potency at reducing pulmonary viral loads in animal models.

  9. Drug

    Edoxudine

    go.drugbank.com/drugs/DB13421
    ApprovedWithdrawn

    Edoxudine is a deoxythymidine analog with activity against herpes simplex virus. It is a potent and selective inhibitor of herpes simplex virus type 1 and 2. The obtained product is an antiviral ointment. The activity of edoxudine agains...

  10. Drug

    Chikungunya vaccine (live, attenuated)

    go.drugbank.com/drugs/DB18701
    ApprovedInvestigational

    [A262051] Prior to 2013, chikungunya virus cases and outbreaks had been identified in countries in Africa, Asia, Europe, and the Indian and Pacific Oceans.

    Categories: Complex Mixtures